Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Recent & Breaking News (NDAQ:ACOR)

Esteve Launches INBRIJA® in Germany

Business Wire June 16, 2022

Acorda Therapeutics Reports First Quarter 2022 Financial Results

Business Wire May 11, 2022

Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America

Business Wire May 11, 2022

Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022

Business Wire May 4, 2022

Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Business Wire March 9, 2022

Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022

Business Wire February 24, 2022

Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Business Wire January 4, 2022

John Varian Joins Acorda Therapeutics Board of Directors

Business Wire January 3, 2022

Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team

Business Wire November 9, 2021

Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany

Business Wire November 9, 2021

Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021

Business Wire November 2, 2021

Acorda Therapeutics Announces Corporate Restructuring, Management Changes

Business Wire September 9, 2021

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

PR Newswire September 25, 2017

Acorda to Present at the Cantor Fitzgerald Global Healthcare Conference

Business Wire September 13, 2017

Stocks Under Scanner in the Biotech Space -- Acorda Therapeutics, Advaxis, Xbiotech, and Akebia Therapeutics

PR Newswire September 11, 2017

INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc.

Business Wire September 8, 2017

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

Business Wire September 5, 2017

Acorda Adopts Shareholder Rights Plan

Business Wire September 1, 2017

SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc.

Business Wire August 30, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acorda Therapeutics Inc. (ACOR)

PR Newswire August 30, 2017